Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study-Reference-Cited by-同舟云学术

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

Published:2022-01 Issue:1 Volume:10 Page:11-25
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Wechsler Michael E,Ford Linda B,Maspero Jorge F,Pavord Ian D,Papi Alberto,Bourdin Arnaud,Watz Henrik,Castro Mario,Nenasheva Natalia M,Tohda Yuji,Langton David,Cardona Guido,Domingo Christian,Park Hae Sim,Chapman Kenneth R,Mao Xuezhou,Zhang Yi,Khan Asif H,Deniz Yamo,Rowe Paul J,Kapoor Upender,Khokhar Faisal A,Mannent Leda P,Ruddy Marcella,Laws Elizabeth,Amin Nikhil,Hardin Megan

Funder

Regeneron Pharmaceuticals Inc

Sanofi US

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference20 articles.

1. A 15-year follow-up study of ventilatory function in adults with asthma;Lange;N Engl J Med,1998

2. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis;Lange;Lancet Respir Med,2016

3. The natural history of asthma;Reed;J Allergy Clin Immunol,2006

4. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study;Dompeling;Ann Intern Med,1993

5. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma;Berry;Clin Exp Allergy,2005

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Granulomatous hyperinflammatory state induced by dupilumab treatment for eosinophilic esophagitis;Journal of Allergy and Clinical Immunology: Global;2024-11

2. Mechanism of miR-130b-3p in relieving airway inflammation in asthma through HMGB1-TLR4-DRP1 axis;2024-09-13

3. Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study;Respiratory Medicine;2024-09

4. Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma;Allergology International;2024-09

5. Biologics in Asthma;Immunology and Allergy Clinics of North America;2024-09